Actively Recruiting

Phase 2
Age: 18Years +
All Genders
NCT04332367

Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance

Led by Abramson Cancer Center at Penn Medicine · Updated on 2026-01-07

59

Participants Needed

1

Research Sites

295 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of this study is to determine if the combination of the three anti-cancer drugs carboplatin, paclitaxel, and ramucirumab is helpful in shrinking tumors or delaying tumor growth in participants with non-small cell lung cancer. This study will also assess whether it is safe to combine these drugs.

CONDITIONS

Official Title

Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults aged 18 years or older
  • Diagnosed with advanced non-squamous NSCLC (Stage IV or recurrent after initial curative intent therapy)
  • Previous treatment with 4-6 cycles of pemetrexed, carboplatin, and/or pembrolizumab
  • Disease progression after at least 18 weeks of maintenance therapy with pemetrexed, pembrolizumab, or their combination
  • Performance status (PS) of 0-1
Not Eligible

You will not qualify if you...

  • Presence of a driver mutation that can be treated with targeted therapy
  • Having another active invasive cancer that requires ongoing treatment
  • Sensory neuropathy of grade 2 or higher
  • Untreated brain metastases
  • History of bleeding disorders or recent significant coughing up of blood (more than half a teaspoon in the past 2 months)

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Abramson Cancer Center of the University of Pennsylvania

Philadelphia, Pennsylvania, United States, 19104

Actively Recruiting

Loading map...

Research Team

M

Melissa Volpe, BA

CONTACT

M

Melina Marmarelis, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here